| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Percutaneous Coronary Intervention | 82 | 2024 | 549 | 7.540 |
Why?
|
| Coronary Angiography | 43 | 2024 | 328 | 4.080 |
Why?
|
| Myocardial Infarction | 49 | 2023 | 1211 | 3.240 |
Why?
|
| Registries | 72 | 2024 | 2410 | 2.970 |
Why?
|
| Transcatheter Aortic Valve Replacement | 12 | 2025 | 154 | 2.590 |
Why?
|
| Coronary Artery Disease | 29 | 2024 | 750 | 2.540 |
Why?
|
| Aortic Valve Stenosis | 12 | 2024 | 256 | 2.210 |
Why?
|
| Cardiac Catheterization | 25 | 2024 | 559 | 2.040 |
Why?
|
| Angioplasty, Balloon, Coronary | 25 | 2014 | 156 | 1.990 |
Why?
|
| Cardiology | 12 | 2022 | 362 | 1.400 |
Why?
|
| Radial Artery | 17 | 2022 | 75 | 1.350 |
Why?
|
| Hemorrhage | 23 | 2024 | 822 | 1.300 |
Why?
|
| Hospital Mortality | 30 | 2024 | 1038 | 1.140 |
Why?
|
| Drug-Eluting Stents | 13 | 2019 | 88 | 1.130 |
Why?
|
| Cardiovascular Diseases | 13 | 2023 | 2191 | 1.100 |
Why?
|
| Acute Coronary Syndrome | 11 | 2024 | 297 | 1.060 |
Why?
|
| Femoral Artery | 14 | 2022 | 190 | 0.980 |
Why?
|
| Ultrasonography, Interventional | 7 | 2015 | 166 | 0.950 |
Why?
|
| Platelet Aggregation Inhibitors | 14 | 2019 | 499 | 0.920 |
Why?
|
| Treatment Outcome | 80 | 2025 | 11794 | 0.910 |
Why?
|
| Heart Valve Prosthesis | 4 | 2021 | 129 | 0.910 |
Why?
|
| Aged | 123 | 2025 | 26217 | 0.890 |
Why?
|
| Contrast Media | 9 | 2024 | 497 | 0.870 |
Why?
|
| Ticlopidine | 7 | 2016 | 52 | 0.860 |
Why?
|
| United States | 86 | 2024 | 16126 | 0.850 |
Why?
|
| Pacemaker, Artificial | 19 | 2018 | 128 | 0.810 |
Why?
|
| Aortic Valve | 9 | 2024 | 364 | 0.810 |
Why?
|
| Coronary Stenosis | 8 | 2014 | 40 | 0.790 |
Why?
|
| Influenza Pandemic, 1918-1919 | 1 | 2023 | 1 | 0.780 |
Why?
|
| Coronary Artery Bypass | 11 | 2021 | 268 | 0.780 |
Why?
|
| Postoperative Complications | 14 | 2025 | 2977 | 0.760 |
Why?
|
| Imaging, Three-Dimensional | 13 | 2016 | 583 | 0.750 |
Why?
|
| Catheterization, Peripheral | 7 | 2022 | 120 | 0.740 |
Why?
|
| Coronary Vessels | 13 | 2019 | 246 | 0.720 |
Why?
|
| Humans | 209 | 2025 | 145783 | 0.700 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 7 | 2019 | 71 | 0.700 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2023 | 159 | 0.690 |
Why?
|
| Risk Factors | 49 | 2024 | 10919 | 0.680 |
Why?
|
| Shock, Cardiogenic | 10 | 2023 | 65 | 0.680 |
Why?
|
| Stents | 15 | 2016 | 564 | 0.670 |
Why?
|
| Electrocardiography | 21 | 2020 | 668 | 0.650 |
Why?
|
| Time Factors | 38 | 2024 | 7134 | 0.630 |
Why?
|
| Acute Kidney Injury | 5 | 2024 | 874 | 0.630 |
Why?
|
| Computer Simulation | 7 | 2014 | 1003 | 0.610 |
Why?
|
| Hospitals | 10 | 2022 | 733 | 0.600 |
Why?
|
| Middle Aged | 100 | 2024 | 36309 | 0.590 |
Why?
|
| Radiography, Interventional | 8 | 2019 | 128 | 0.580 |
Why?
|
| Male | 137 | 2025 | 73011 | 0.580 |
Why?
|
| Coronary Disease | 10 | 2012 | 382 | 0.570 |
Why?
|
| Female | 136 | 2025 | 79045 | 0.560 |
Why?
|
| Risk Assessment | 26 | 2024 | 3752 | 0.560 |
Why?
|
| Coronary Restenosis | 3 | 2013 | 22 | 0.540 |
Why?
|
| ST Elevation Myocardial Infarction | 4 | 2023 | 64 | 0.520 |
Why?
|
| Fractional Flow Reserve, Myocardial | 2 | 2013 | 10 | 0.480 |
Why?
|
| Echocardiography, Three-Dimensional | 4 | 2019 | 71 | 0.480 |
Why?
|
| Practice Patterns, Physicians' | 10 | 2019 | 1372 | 0.470 |
Why?
|
| Myocardial Ischemia | 6 | 2013 | 285 | 0.470 |
Why?
|
| Models, Cardiovascular | 3 | 2013 | 196 | 0.470 |
Why?
|
| Hospitals, High-Volume | 6 | 2021 | 50 | 0.470 |
Why?
|
| Cardiac Pacing, Artificial | 13 | 2007 | 84 | 0.460 |
Why?
|
| Graft Occlusion, Vascular | 4 | 2019 | 40 | 0.460 |
Why?
|
| Follow-Up Studies | 29 | 2021 | 5428 | 0.450 |
Why?
|
| Hospitals, Low-Volume | 5 | 2021 | 26 | 0.440 |
Why?
|
| Aged, 80 and over | 39 | 2025 | 8347 | 0.440 |
Why?
|
| Endovascular Procedures | 4 | 2025 | 390 | 0.440 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 9 | 2019 | 122 | 0.430 |
Why?
|
| Allografts | 1 | 2015 | 152 | 0.430 |
Why?
|
| Prasugrel Hydrochloride | 5 | 2016 | 22 | 0.420 |
Why?
|
| Medicare | 12 | 2021 | 904 | 0.420 |
Why?
|
| Fluoroscopy | 7 | 2021 | 180 | 0.420 |
Why?
|
| Survival Rate | 12 | 2021 | 2094 | 0.420 |
Why?
|
| Patient Readmission | 7 | 2024 | 773 | 0.420 |
Why?
|
| Intra-Aortic Balloon Pumping | 4 | 2021 | 19 | 0.410 |
Why?
|
| Vascular Diseases | 2 | 2015 | 252 | 0.390 |
Why?
|
| Computer-Assisted Instruction | 1 | 2013 | 70 | 0.380 |
Why?
|
| Heart Arrest | 4 | 2021 | 411 | 0.370 |
Why?
|
| Quality Indicators, Health Care | 5 | 2021 | 336 | 0.370 |
Why?
|
| Postoperative Hemorrhage | 4 | 2016 | 105 | 0.370 |
Why?
|
| Heart Valve Prosthesis Implantation | 4 | 2024 | 198 | 0.370 |
Why?
|
| Time-to-Treatment | 4 | 2024 | 251 | 0.370 |
Why?
|
| Retrospective Studies | 40 | 2025 | 17330 | 0.370 |
Why?
|
| Coronary Thrombosis | 2 | 2012 | 25 | 0.370 |
Why?
|
| Heart-Assist Devices | 4 | 2023 | 568 | 0.360 |
Why?
|
| Length of Stay | 7 | 2024 | 1350 | 0.360 |
Why?
|
| Heart Defects, Congenital | 4 | 2021 | 910 | 0.350 |
Why?
|
| Patient Discharge | 6 | 2024 | 995 | 0.340 |
Why?
|
| Decision Support Techniques | 6 | 2024 | 480 | 0.340 |
Why?
|
| Heart Failure | 3 | 2023 | 2326 | 0.330 |
Why?
|
| Teaching | 1 | 2013 | 237 | 0.330 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 2 | 2024 | 121 | 0.330 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 391 | 0.320 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 384 | 0.320 |
Why?
|
| Coronary Aneurysm | 1 | 2010 | 17 | 0.320 |
Why?
|
| Heart Block | 8 | 2018 | 41 | 0.320 |
Why?
|
| Embolic Protection Devices | 2 | 2024 | 12 | 0.310 |
Why?
|
| Echocardiography, Transesophageal | 4 | 2021 | 132 | 0.310 |
Why?
|
| Hemostatic Techniques | 3 | 2020 | 52 | 0.300 |
Why?
|
| Arrhythmias, Cardiac | 7 | 2023 | 356 | 0.300 |
Why?
|
| Practice Guidelines as Topic | 6 | 2020 | 1582 | 0.300 |
Why?
|
| Peptide Fragments | 6 | 2020 | 697 | 0.290 |
Why?
|
| Clinical Competence | 7 | 2017 | 1247 | 0.290 |
Why?
|
| Anticoagulants | 6 | 2015 | 748 | 0.290 |
Why?
|
| Image Enhancement | 2 | 2010 | 200 | 0.290 |
Why?
|
| Heart Transplantation | 1 | 2015 | 680 | 0.290 |
Why?
|
| Predictive Value of Tests | 16 | 2020 | 2123 | 0.280 |
Why?
|
| Databases, Factual | 6 | 2024 | 1491 | 0.280 |
Why?
|
| Radiation Dosage | 7 | 2016 | 193 | 0.280 |
Why?
|
| Education, Medical, Graduate | 1 | 2013 | 562 | 0.280 |
Why?
|
| Cardiology Service, Hospital | 2 | 2020 | 29 | 0.270 |
Why?
|
| Hirudins | 6 | 2020 | 53 | 0.270 |
Why?
|
| Veterans | 2 | 2019 | 1642 | 0.260 |
Why?
|
| Myocardial Revascularization | 6 | 2016 | 85 | 0.260 |
Why?
|
| Patient Simulation | 1 | 2008 | 43 | 0.260 |
Why?
|
| Angioplasty | 2 | 2010 | 50 | 0.260 |
Why?
|
| Prospective Studies | 22 | 2024 | 8078 | 0.250 |
Why?
|
| Incidence | 12 | 2020 | 2934 | 0.240 |
Why?
|
| Device Removal | 3 | 2005 | 142 | 0.240 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2021 | 303 | 0.240 |
Why?
|
| Defibrillators, Implantable | 3 | 2022 | 387 | 0.240 |
Why?
|
| Quality Improvement | 5 | 2019 | 1296 | 0.240 |
Why?
|
| Workload | 2 | 2019 | 169 | 0.230 |
Why?
|
| Societies, Medical | 4 | 2020 | 900 | 0.230 |
Why?
|
| Multicenter Studies as Topic | 2 | 2024 | 413 | 0.230 |
Why?
|
| Pandemics | 4 | 2023 | 1711 | 0.230 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 2019 | 63 | 0.230 |
Why?
|
| Antithrombins | 4 | 2020 | 71 | 0.220 |
Why?
|
| Drug Substitution | 2 | 2016 | 63 | 0.220 |
Why?
|
| Consensus | 4 | 2020 | 479 | 0.220 |
Why?
|
| Prognosis | 8 | 2024 | 4330 | 0.220 |
Why?
|
| Advisory Committees | 2 | 2020 | 229 | 0.220 |
Why?
|
| Comorbidity | 8 | 2019 | 1662 | 0.220 |
Why?
|
| Radiographic Image Enhancement | 3 | 2006 | 57 | 0.220 |
Why?
|
| Propensity Score | 7 | 2020 | 377 | 0.220 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2024 | 1752 | 0.220 |
Why?
|
| American Heart Association | 3 | 2016 | 358 | 0.210 |
Why?
|
| Odds Ratio | 10 | 2017 | 1083 | 0.210 |
Why?
|
| Heart Septum | 2 | 2015 | 27 | 0.210 |
Why?
|
| Peripheral Vascular Diseases | 2 | 2019 | 104 | 0.210 |
Why?
|
| Education, Medical | 1 | 2008 | 276 | 0.210 |
Why?
|
| Angiography | 4 | 2021 | 208 | 0.200 |
Why?
|
| Cardiologists | 2 | 2021 | 45 | 0.200 |
Why?
|
| Thrombolytic Therapy | 3 | 2020 | 164 | 0.200 |
Why?
|
| Learning Curve | 2 | 2015 | 71 | 0.200 |
Why?
|
| Comparative Effectiveness Research | 6 | 2016 | 169 | 0.200 |
Why?
|
| Heart Diseases | 3 | 2019 | 341 | 0.200 |
Why?
|
| Vascular Fistula | 1 | 2024 | 22 | 0.200 |
Why?
|
| Kidney Diseases | 2 | 2023 | 426 | 0.200 |
Why?
|
| Aspirin | 3 | 2015 | 406 | 0.200 |
Why?
|
| Hypothermia, Induced | 1 | 2024 | 96 | 0.190 |
Why?
|
| Algorithms | 8 | 2020 | 1851 | 0.190 |
Why?
|
| Certification | 2 | 2015 | 119 | 0.190 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2015 | 143 | 0.190 |
Why?
|
| Stroke | 7 | 2024 | 1271 | 0.190 |
Why?
|
| Aorta, Thoracic | 1 | 2025 | 287 | 0.190 |
Why?
|
| Healthcare Disparities | 3 | 2020 | 736 | 0.190 |
Why?
|
| Betacoronavirus | 3 | 2020 | 289 | 0.190 |
Why?
|
| Myocardial Reperfusion | 2 | 2013 | 56 | 0.190 |
Why?
|
| Cineangiography | 5 | 2009 | 9 | 0.190 |
Why?
|
| Internship and Residency | 1 | 2013 | 1269 | 0.190 |
Why?
|
| Heart Injuries | 1 | 2023 | 42 | 0.190 |
Why?
|
| Research Design | 3 | 2022 | 1139 | 0.190 |
Why?
|
| Intraoperative Care | 2 | 2013 | 63 | 0.180 |
Why?
|
| Age Factors | 9 | 2020 | 3346 | 0.180 |
Why?
|
| Heart Ventricles | 6 | 2018 | 756 | 0.180 |
Why?
|
| Severity of Illness Index | 12 | 2020 | 2933 | 0.180 |
Why?
|
| Enoxaparin | 2 | 2015 | 68 | 0.180 |
Why?
|
| History, 20th Century | 1 | 2023 | 328 | 0.170 |
Why?
|
| Technology Transfer | 1 | 2021 | 9 | 0.170 |
Why?
|
| Multimodal Imaging | 2 | 2019 | 129 | 0.170 |
Why?
|
| Sex Factors | 5 | 2014 | 2110 | 0.170 |
Why?
|
| Forecasting | 2 | 2022 | 390 | 0.170 |
Why?
|
| Guideline Adherence | 3 | 2015 | 587 | 0.170 |
Why?
|
| Reproducibility of Results | 9 | 2021 | 3418 | 0.160 |
Why?
|
| Inpatients | 2 | 2024 | 553 | 0.160 |
Why?
|
| Physicians | 3 | 2015 | 956 | 0.160 |
Why?
|
| Tachycardia, Ventricular | 2 | 2024 | 180 | 0.160 |
Why?
|
| Retreatment | 3 | 2019 | 80 | 0.160 |
Why?
|
| Surgicenters | 1 | 2020 | 5 | 0.160 |
Why?
|
| Breast Neoplasms | 1 | 2013 | 2393 | 0.160 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2019 | 668 | 0.160 |
Why?
|
| Ischemia | 3 | 2009 | 422 | 0.160 |
Why?
|
| Longitudinal Studies | 10 | 2019 | 2968 | 0.160 |
Why?
|
| Saphenous Vein | 3 | 2015 | 37 | 0.160 |
Why?
|
| Septal Occluder Device | 2 | 2018 | 37 | 0.160 |
Why?
|
| Manuals as Topic | 1 | 2020 | 16 | 0.160 |
Why?
|
| Proportional Hazards Models | 8 | 2016 | 1330 | 0.160 |
Why?
|
| Assisted Circulation | 2 | 2021 | 26 | 0.150 |
Why?
|
| Ethanol | 2 | 2015 | 631 | 0.150 |
Why?
|
| Chi-Square Distribution | 6 | 2017 | 528 | 0.150 |
Why?
|
| Thrombosis | 3 | 2016 | 400 | 0.150 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2021 | 390 | 0.150 |
Why?
|
| Absorbable Implants | 1 | 2019 | 38 | 0.140 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2019 | 37 | 0.140 |
Why?
|
| Popliteal Artery | 2 | 2009 | 62 | 0.140 |
Why?
|
| Rural Health Services | 1 | 2020 | 138 | 0.140 |
Why?
|
| Logistic Models | 8 | 2017 | 2139 | 0.140 |
Why?
|
| Angina Pectoris | 1 | 2019 | 76 | 0.140 |
Why?
|
| Electrodes, Implanted | 5 | 1999 | 114 | 0.140 |
Why?
|
| Atrioventricular Block | 1 | 2019 | 44 | 0.140 |
Why?
|
| Infection Control | 1 | 2020 | 173 | 0.140 |
Why?
|
| Medicaid | 2 | 2013 | 467 | 0.140 |
Why?
|
| Models, Anatomic | 2 | 2009 | 87 | 0.140 |
Why?
|
| Vascular System Injuries | 1 | 2019 | 81 | 0.140 |
Why?
|
| Recombinant Proteins | 8 | 2020 | 1368 | 0.140 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2015 | 783 | 0.130 |
Why?
|
| Health Care Costs | 2 | 2019 | 425 | 0.130 |
Why?
|
| Quality of Health Care | 2 | 2016 | 693 | 0.130 |
Why?
|
| Myocardium | 1 | 2023 | 935 | 0.130 |
Why?
|
| Rotation | 5 | 2011 | 121 | 0.130 |
Why?
|
| Creatinine | 4 | 2024 | 515 | 0.130 |
Why?
|
| Subacute Care | 1 | 2018 | 84 | 0.130 |
Why?
|
| Cohort Studies | 11 | 2023 | 6033 | 0.130 |
Why?
|
| Efficiency, Organizational | 1 | 2018 | 141 | 0.130 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 2016 | 10 | 0.120 |
Why?
|
| Tissue Scaffolds | 1 | 2019 | 221 | 0.120 |
Why?
|
| Vascular Surgical Procedures | 3 | 2009 | 343 | 0.120 |
Why?
|
| Atrial Fibrillation | 3 | 2007 | 558 | 0.120 |
Why?
|
| Leg | 2 | 2009 | 242 | 0.120 |
Why?
|
| Angioplasty, Balloon | 2 | 2007 | 94 | 0.120 |
Why?
|
| Equipment Design | 7 | 2014 | 525 | 0.120 |
Why?
|
| Aortography | 1 | 2016 | 52 | 0.120 |
Why?
|
| Multidetector Computed Tomography | 1 | 2016 | 40 | 0.120 |
Why?
|
| Long Term Adverse Effects | 1 | 2015 | 13 | 0.120 |
Why?
|
| Heart Valve Diseases | 2 | 2015 | 151 | 0.120 |
Why?
|
| Drug Therapy, Combination | 2 | 2015 | 1043 | 0.110 |
Why?
|
| Syncope | 1 | 2016 | 56 | 0.110 |
Why?
|
| Proton Pump Inhibitors | 1 | 2016 | 109 | 0.110 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2015 | 43 | 0.110 |
Why?
|
| Blood Loss, Surgical | 2 | 2013 | 114 | 0.110 |
Why?
|
| Unnecessary Procedures | 1 | 2015 | 54 | 0.110 |
Why?
|
| Metals | 1 | 2016 | 136 | 0.110 |
Why?
|
| Anterior Wall Myocardial Infarction | 1 | 2015 | 4 | 0.110 |
Why?
|
| Education, Medical, Continuing | 2 | 2013 | 134 | 0.110 |
Why?
|
| Injections | 3 | 2014 | 199 | 0.110 |
Why?
|
| Vascular Grafting | 1 | 2015 | 15 | 0.110 |
Why?
|
| Punctures | 3 | 2020 | 41 | 0.110 |
Why?
|
| Elective Surgical Procedures | 2 | 2013 | 203 | 0.110 |
Why?
|
| Ablation Techniques | 1 | 2015 | 36 | 0.110 |
Why?
|
| Computed Tomography Angiography | 1 | 2016 | 146 | 0.110 |
Why?
|
| Platelet Activation | 1 | 2015 | 99 | 0.110 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 498 | 0.110 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2015 | 58 | 0.100 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 948 | 0.100 |
Why?
|
| Quality Assurance, Health Care | 2 | 2020 | 342 | 0.100 |
Why?
|
| Radiation Injuries | 1 | 2015 | 149 | 0.100 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2014 | 63 | 0.100 |
Why?
|
| Catheter Ablation | 1 | 2018 | 355 | 0.100 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2013 | 6 | 0.100 |
Why?
|
| Pharmacogenetics | 1 | 2015 | 175 | 0.100 |
Why?
|
| Thrombectomy | 2 | 2012 | 78 | 0.100 |
Why?
|
| Prosthesis Design | 2 | 2013 | 356 | 0.100 |
Why?
|
| Clinical Decision-Making | 3 | 2024 | 364 | 0.100 |
Why?
|
| Warfarin | 1 | 2015 | 179 | 0.100 |
Why?
|
| Academies and Institutes | 1 | 2013 | 61 | 0.100 |
Why?
|
| Radiation | 1 | 2013 | 24 | 0.100 |
Why?
|
| Withholding Treatment | 1 | 2014 | 80 | 0.100 |
Why?
|
| Blood Vessel Prosthesis | 2 | 2006 | 140 | 0.100 |
Why?
|
| Hemostasis, Surgical | 1 | 2013 | 25 | 0.100 |
Why?
|
| Renal Dialysis | 3 | 2014 | 466 | 0.100 |
Why?
|
| Cardiac Volume | 2 | 2003 | 14 | 0.090 |
Why?
|
| Heparin | 2 | 2015 | 247 | 0.090 |
Why?
|
| Patient Selection | 5 | 2019 | 739 | 0.090 |
Why?
|
| Coronary Occlusion | 1 | 2012 | 20 | 0.090 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2015 | 265 | 0.090 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 1 | 2012 | 16 | 0.090 |
Why?
|
| Wound Closure Techniques | 1 | 2012 | 13 | 0.090 |
Why?
|
| Fibrinolytic Agents | 2 | 2009 | 297 | 0.090 |
Why?
|
| Medical Audit | 1 | 2012 | 77 | 0.090 |
Why?
|
| Medication Adherence | 1 | 2016 | 540 | 0.090 |
Why?
|
| Diagnosis, Differential | 3 | 2020 | 1512 | 0.090 |
Why?
|
| Adult | 19 | 2015 | 40881 | 0.090 |
Why?
|
| Embolism | 1 | 2012 | 48 | 0.090 |
Why?
|
| Aneurysm, False | 1 | 2012 | 46 | 0.090 |
Why?
|
| Angina, Unstable | 1 | 2012 | 83 | 0.090 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 1101 | 0.090 |
Why?
|
| Blood Platelets | 1 | 2015 | 379 | 0.090 |
Why?
|
| Triiodobenzoic Acids | 2 | 2011 | 6 | 0.090 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2012 | 82 | 0.090 |
Why?
|
| Insurance Claim Review | 1 | 2012 | 83 | 0.090 |
Why?
|
| Tomography, Optical Coherence | 1 | 2013 | 270 | 0.090 |
Why?
|
| Quality of Life | 5 | 2019 | 3211 | 0.080 |
Why?
|
| Ambulatory Care | 1 | 2016 | 610 | 0.080 |
Why?
|
| Polyethylene Terephthalates | 1 | 1991 | 21 | 0.080 |
Why?
|
| Diagnostic Imaging | 1 | 2013 | 337 | 0.080 |
Why?
|
| Phantoms, Imaging | 2 | 2002 | 159 | 0.080 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2019 | 779 | 0.080 |
Why?
|
| Ventricular Function, Left | 1 | 2014 | 544 | 0.080 |
Why?
|
| Manikins | 1 | 2010 | 37 | 0.080 |
Why?
|
| Movement | 2 | 2009 | 293 | 0.080 |
Why?
|
| Cardiovascular Agents | 4 | 2016 | 166 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2014 | 971 | 0.080 |
Why?
|
| Sensitivity and Specificity | 4 | 2019 | 2000 | 0.080 |
Why?
|
| Observer Variation | 3 | 2011 | 357 | 0.070 |
Why?
|
| Multivariate Analysis | 4 | 2014 | 1547 | 0.070 |
Why?
|
| Glomerular Filtration Rate | 3 | 2023 | 765 | 0.070 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2009 | 38 | 0.070 |
Why?
|
| Prosthesis Failure | 1 | 2010 | 125 | 0.070 |
Why?
|
| Recurrence | 4 | 2016 | 1139 | 0.070 |
Why?
|
| Equipment Failure | 2 | 2005 | 115 | 0.070 |
Why?
|
| Drug Administration Schedule | 3 | 2019 | 782 | 0.070 |
Why?
|
| Cause of Death | 3 | 2020 | 472 | 0.070 |
Why?
|
| Prevalence | 5 | 2019 | 2875 | 0.070 |
Why?
|
| Vascular Closure Devices | 2 | 2020 | 6 | 0.070 |
Why?
|
| Liver Transplantation | 1 | 2015 | 827 | 0.070 |
Why?
|
| Preoperative Period | 2 | 2021 | 149 | 0.070 |
Why?
|
| Carotid Stenosis | 1 | 2009 | 107 | 0.070 |
Why?
|
| Hyperbaric Oxygenation | 2 | 1998 | 39 | 0.070 |
Why?
|
| Heart Atria | 6 | 1990 | 141 | 0.070 |
Why?
|
| Aftercare | 2 | 2022 | 222 | 0.070 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 2383 | 0.070 |
Why?
|
| Embolization, Therapeutic | 1 | 2010 | 243 | 0.070 |
Why?
|
| Cardiac Output, Low | 1 | 2007 | 53 | 0.060 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2009 | 251 | 0.060 |
Why?
|
| Extremities | 1 | 2007 | 142 | 0.060 |
Why?
|
| Stroke Volume | 5 | 2015 | 655 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2014 | 2770 | 0.060 |
Why?
|
| Tuberculosis, Spinal | 1 | 2006 | 8 | 0.060 |
Why?
|
| Tissue Plasminogen Activator | 2 | 1998 | 248 | 0.060 |
Why?
|
| Survival Analysis | 4 | 2013 | 1378 | 0.060 |
Why?
|
| Mortality | 3 | 2016 | 381 | 0.060 |
Why?
|
| Hemodynamics | 3 | 2020 | 1118 | 0.060 |
Why?
|
| Treatment Refusal | 1 | 2006 | 99 | 0.060 |
Why?
|
| Systole | 2 | 1983 | 181 | 0.060 |
Why?
|
| Biomarkers | 4 | 2023 | 4302 | 0.060 |
Why?
|
| Lower Extremity | 1 | 2009 | 450 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2024 | 75 | 0.050 |
Why?
|
| Vascular Patency | 3 | 2012 | 121 | 0.050 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 5925 | 0.050 |
Why?
|
| Sirolimus | 1 | 2006 | 282 | 0.050 |
Why?
|
| Prosthesis Implantation | 1 | 2006 | 156 | 0.050 |
Why?
|
| Intraoperative Complications | 2 | 2018 | 157 | 0.050 |
Why?
|
| Equipment Safety | 1 | 2004 | 38 | 0.050 |
Why?
|
| Ventricular Fibrillation | 1 | 2024 | 64 | 0.050 |
Why?
|
| Patient Safety | 2 | 2020 | 356 | 0.050 |
Why?
|
| Intracranial Embolism | 1 | 2024 | 34 | 0.050 |
Why?
|
| Risk | 3 | 2012 | 923 | 0.050 |
Why?
|
| Protective Factors | 1 | 2024 | 99 | 0.050 |
Why?
|
| Electric Countershock | 1 | 2005 | 126 | 0.050 |
Why?
|
| Adenosine | 2 | 2016 | 255 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2012 | 1101 | 0.050 |
Why?
|
| Prosthesis-Related Infections | 1 | 2005 | 98 | 0.050 |
Why?
|
| Peptides | 1 | 2009 | 999 | 0.050 |
Why?
|
| United States Food and Drug Administration | 2 | 2016 | 208 | 0.050 |
Why?
|
| Reoperation | 2 | 2021 | 637 | 0.050 |
Why?
|
| Blood Vessel Prosthesis Implantation | 2 | 2004 | 228 | 0.050 |
Why?
|
| Troponin | 1 | 2023 | 50 | 0.050 |
Why?
|
| Catheters | 1 | 2023 | 74 | 0.050 |
Why?
|
| Patient Preference | 2 | 2016 | 223 | 0.050 |
Why?
|
| Disability Evaluation | 1 | 2024 | 311 | 0.050 |
Why?
|
| Pyridines | 1 | 2006 | 609 | 0.040 |
Why?
|
| Risk Adjustment | 2 | 2013 | 85 | 0.040 |
Why?
|
| Kidney | 2 | 2023 | 1497 | 0.040 |
Why?
|
| Physical Exertion | 1 | 1982 | 205 | 0.040 |
Why?
|
| Diagnosis-Related Groups | 1 | 2021 | 35 | 0.040 |
Why?
|
| Myocardial Contraction | 1 | 1982 | 293 | 0.040 |
Why?
|
| Patient Participation | 1 | 2024 | 446 | 0.040 |
Why?
|
| Endocardium | 2 | 1990 | 31 | 0.040 |
Why?
|
| Costs and Cost Analysis | 2 | 2019 | 221 | 0.040 |
Why?
|
| Curriculum | 1 | 2008 | 1074 | 0.040 |
Why?
|
| Hospitals, Teaching | 1 | 2021 | 121 | 0.040 |
Why?
|
| Mass Screening | 1 | 2009 | 1361 | 0.040 |
Why?
|
| Pressure | 2 | 2012 | 226 | 0.040 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2021 | 115 | 0.040 |
Why?
|
| Florida | 1 | 2020 | 117 | 0.040 |
Why?
|
| Population Density | 1 | 2020 | 89 | 0.040 |
Why?
|
| Matched-Pair Analysis | 1 | 2020 | 37 | 0.040 |
Why?
|
| International Classification of Diseases | 1 | 2021 | 150 | 0.040 |
Why?
|
| Heart Rate | 4 | 2011 | 856 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 229 | 0.040 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2003 | 394 | 0.040 |
Why?
|
| Tachycardia, Supraventricular | 2 | 1990 | 49 | 0.040 |
Why?
|
| Organizational Innovation | 1 | 2020 | 119 | 0.040 |
Why?
|
| Device Approval | 1 | 2019 | 19 | 0.040 |
Why?
|
| Combined Modality Therapy | 3 | 2012 | 1271 | 0.040 |
Why?
|
| Travel | 1 | 2020 | 136 | 0.040 |
Why?
|
| Models, Statistical | 2 | 2014 | 672 | 0.040 |
Why?
|
| Anatomic Landmarks | 1 | 2019 | 31 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2019 | 176 | 0.040 |
Why?
|
| Patient-Specific Modeling | 1 | 2019 | 45 | 0.040 |
Why?
|
| Hospitals, Urban | 1 | 2019 | 142 | 0.030 |
Why?
|
| Writing | 1 | 2020 | 101 | 0.030 |
Why?
|
| Colorado | 3 | 2019 | 4556 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 2 | 2012 | 644 | 0.030 |
Why?
|
| Plasminogen Activators | 1 | 1997 | 7 | 0.030 |
Why?
|
| Data Collection | 1 | 2020 | 643 | 0.030 |
Why?
|
| Exercise Test | 3 | 2014 | 630 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2020 | 375 | 0.030 |
Why?
|
| Pulmonary Artery | 1 | 2023 | 1129 | 0.030 |
Why?
|
| Social Media | 1 | 2020 | 167 | 0.030 |
Why?
|
| Adenosine Diphosphate | 1 | 2016 | 83 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 740 | 0.030 |
Why?
|
| Disease Management | 1 | 2020 | 653 | 0.030 |
Why?
|
| Radiologic Health | 1 | 2015 | 4 | 0.030 |
Why?
|
| Automation | 1 | 2016 | 104 | 0.030 |
Why?
|
| Netherlands | 1 | 2015 | 84 | 0.030 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2015 | 45 | 0.030 |
Why?
|
| Platelet Function Tests | 1 | 2015 | 35 | 0.030 |
Why?
|
| Radiation Exposure | 1 | 2016 | 63 | 0.030 |
Why?
|
| Drug Costs | 1 | 2016 | 117 | 0.030 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2016 | 138 | 0.030 |
Why?
|
| Health Expenditures | 1 | 2016 | 194 | 0.030 |
Why?
|
| Single-Blind Method | 2 | 2007 | 318 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2014 | 18 | 0.030 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2015 | 38 | 0.030 |
Why?
|
| Thrombelastography | 1 | 2015 | 192 | 0.030 |
Why?
|
| Radiology, Interventional | 1 | 1994 | 49 | 0.030 |
Why?
|
| Echocardiography, Stress | 1 | 2014 | 29 | 0.030 |
Why?
|
| Angina, Stable | 1 | 2014 | 18 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2015 | 125 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2015 | 280 | 0.030 |
Why?
|
| Patient Admission | 1 | 2016 | 220 | 0.030 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2014 | 50 | 0.030 |
Why?
|
| Virginia | 1 | 2013 | 57 | 0.020 |
Why?
|
| Atrial Function | 2 | 1990 | 10 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 1062 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2013 | 164 | 0.020 |
Why?
|
| Solvents | 1 | 2014 | 112 | 0.020 |
Why?
|
| Asymptomatic Diseases | 1 | 2014 | 104 | 0.020 |
Why?
|
| Professional Competence | 1 | 2014 | 91 | 0.020 |
Why?
|
| Echocardiography | 2 | 2014 | 648 | 0.020 |
Why?
|
| Foundations | 1 | 2013 | 27 | 0.020 |
Why?
|
| Blood Pressure | 3 | 2011 | 1782 | 0.020 |
Why?
|
| Cladribine | 1 | 1993 | 1 | 0.020 |
Why?
|
| Sinoatrial Node | 2 | 1990 | 27 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2015 | 867 | 0.020 |
Why?
|
| Canada | 1 | 2014 | 432 | 0.020 |
Why?
|
| Research Report | 1 | 2013 | 86 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2015 | 289 | 0.020 |
Why?
|
| Telemetry | 2 | 1989 | 40 | 0.020 |
Why?
|
| Observation | 1 | 2012 | 54 | 0.020 |
Why?
|
| Linear Models | 1 | 2014 | 849 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 330 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2012 | 283 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1993 | 124 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 2028 | 0.020 |
Why?
|
| Posture | 2 | 2009 | 197 | 0.020 |
Why?
|
| Pectoralis Muscles | 1 | 1991 | 18 | 0.020 |
Why?
|
| Esthetics | 1 | 1991 | 50 | 0.020 |
Why?
|
| Software | 1 | 2016 | 680 | 0.020 |
Why?
|
| Consumer Behavior | 1 | 1991 | 69 | 0.020 |
Why?
|
| Age Distribution | 1 | 2011 | 404 | 0.020 |
Why?
|
| Psychomotor Agitation | 1 | 1991 | 69 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2011 | 388 | 0.020 |
Why?
|
| Leukemia | 1 | 1993 | 246 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2012 | 536 | 0.020 |
Why?
|
| Automation, Laboratory | 1 | 2010 | 8 | 0.020 |
Why?
|
| X-Rays | 1 | 2010 | 27 | 0.020 |
Why?
|
| Tachycardia, Paroxysmal | 1 | 1989 | 8 | 0.020 |
Why?
|
| Torsion, Mechanical | 1 | 2009 | 5 | 0.020 |
Why?
|
| Suture Techniques | 1 | 1991 | 137 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2011 | 252 | 0.020 |
Why?
|
| Contraindications | 1 | 2009 | 90 | 0.020 |
Why?
|
| Hospitals, Veterans | 1 | 2011 | 258 | 0.020 |
Why?
|
| Graft Survival | 1 | 2012 | 519 | 0.020 |
Why?
|
| Multiple Myeloma | 1 | 1993 | 309 | 0.020 |
Why?
|
| Medication Errors | 1 | 2009 | 85 | 0.020 |
Why?
|
| Drug Prescriptions | 1 | 2011 | 288 | 0.020 |
Why?
|
| Feasibility Studies | 2 | 2007 | 1115 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2009 | 168 | 0.020 |
Why?
|
| Calibration | 1 | 2009 | 152 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2010 | 178 | 0.020 |
Why?
|
| Europe | 1 | 2009 | 421 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2014 | 3916 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2019 | 6465 | 0.020 |
Why?
|
| Double-Blind Method | 2 | 2003 | 2064 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2007 | 40 | 0.020 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 444 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2009 | 1001 | 0.020 |
Why?
|
| Veins | 1 | 2007 | 69 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2009 | 562 | 0.020 |
Why?
|
| Life Tables | 1 | 2006 | 21 | 0.020 |
Why?
|
| Wound Healing | 1 | 2009 | 355 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 2009 | 860 | 0.010 |
Why?
|
| Coronary Circulation | 1 | 1986 | 134 | 0.010 |
Why?
|
| Drug Implants | 1 | 2006 | 83 | 0.010 |
Why?
|
| Program Evaluation | 1 | 2010 | 944 | 0.010 |
Why?
|
| Pattern Recognition, Automated | 1 | 2006 | 74 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2006 | 185 | 0.010 |
Why?
|
| Artifacts | 1 | 2006 | 143 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2007 | 514 | 0.010 |
Why?
|
| Aorta | 1 | 2007 | 441 | 0.010 |
Why?
|
| Probability | 1 | 2005 | 308 | 0.010 |
Why?
|
| Acute Disease | 1 | 2007 | 1036 | 0.010 |
Why?
|
| Streptokinase | 2 | 1998 | 9 | 0.010 |
Why?
|
| Diabetes Insipidus | 1 | 1983 | 6 | 0.010 |
Why?
|
| Whole-Body Irradiation | 1 | 2004 | 74 | 0.010 |
Why?
|
| Sputum | 1 | 2006 | 302 | 0.010 |
Why?
|
| Hospitalization | 2 | 2006 | 2461 | 0.010 |
Why?
|
| Antitubercular Agents | 1 | 2006 | 208 | 0.010 |
Why?
|
| Pain | 1 | 2009 | 791 | 0.010 |
Why?
|
| Sound | 1 | 1983 | 55 | 0.010 |
Why?
|
| Technology | 1 | 1983 | 97 | 0.010 |
Why?
|
| Heart Function Tests | 1 | 2003 | 59 | 0.010 |
Why?
|
| Critical Illness | 1 | 2009 | 900 | 0.010 |
Why?
|
| Echocardiography, Doppler | 1 | 2003 | 115 | 0.010 |
Why?
|
| Aging | 1 | 2012 | 1973 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2006 | 777 | 0.010 |
Why?
|
| Artificial Intelligence | 1 | 2006 | 381 | 0.010 |
Why?
|
| Exercise Tolerance | 1 | 2002 | 283 | 0.010 |
Why?
|
| Stress, Mechanical | 1 | 2002 | 494 | 0.010 |
Why?
|
| Exercise | 1 | 1989 | 2205 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2001 | 788 | 0.010 |
Why?
|
| Creatine Kinase | 1 | 1997 | 72 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2003 | 1812 | 0.010 |
Why?
|
| Safety | 1 | 1998 | 358 | 0.010 |
Why?
|
| Subclavian Vein | 1 | 1994 | 15 | 0.010 |
Why?
|
| Traction | 1 | 1994 | 19 | 0.010 |
Why?
|
| Femoral Vein | 1 | 1994 | 38 | 0.010 |
Why?
|
| Staphylococcus epidermidis | 1 | 1994 | 79 | 0.010 |
Why?
|
| Steroids | 1 | 1994 | 160 | 0.010 |
Why?
|
| Cytarabine | 1 | 1993 | 66 | 0.010 |
Why?
|
| Mechlorethamine | 1 | 1993 | 52 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 1993 | 194 | 0.010 |
Why?
|
| Vincristine | 1 | 1993 | 144 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1993 | 145 | 0.010 |
Why?
|
| Adolescent | 3 | 1998 | 22577 | 0.010 |
Why?
|
| Pilot Projects | 1 | 1997 | 1898 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1993 | 887 | 0.010 |
Why?
|
| Atrioventricular Node | 1 | 1990 | 15 | 0.010 |
Why?
|
| Body Constitution | 1 | 1990 | 51 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1993 | 403 | 0.000 |
Why?
|
| Staphylococcal Infections | 1 | 1994 | 393 | 0.000 |
Why?
|
| Respiration | 1 | 1990 | 207 | 0.000 |
Why?
|
| Dizziness | 1 | 1990 | 101 | 0.000 |
Why?
|
| Syndrome | 1 | 1990 | 381 | 0.000 |
Why?
|
| Cardiac Complexes, Premature | 1 | 1988 | 2 | 0.000 |
Why?
|
| Refractory Period, Electrophysiological | 1 | 1988 | 5 | 0.000 |
Why?
|
| Dyspnea | 1 | 1990 | 250 | 0.000 |
Why?
|
| Fatigue | 1 | 1990 | 366 | 0.000 |
Why?
|
| Tromethamine | 1 | 1986 | 2 | 0.000 |
Why?
|
| Citrates | 1 | 1986 | 41 | 0.000 |
Why?
|
| Potassium Chloride | 1 | 1986 | 40 | 0.000 |
Why?
|
| Heart Arrest, Induced | 1 | 1986 | 26 | 0.000 |
Why?
|
| Protein Binding | 1 | 1993 | 2240 | 0.000 |
Why?
|
| Citric Acid | 1 | 1986 | 33 | 0.000 |
Why?
|
| Glutamates | 1 | 1986 | 66 | 0.000 |
Why?
|
| Aspartic Acid | 1 | 1986 | 88 | 0.000 |
Why?
|
| Phosphates | 1 | 1986 | 177 | 0.000 |
Why?
|
| Glutamic Acid | 1 | 1986 | 255 | 0.000 |
Why?
|
| Diuresis | 1 | 1983 | 10 | 0.000 |
Why?
|
| Arginine Vasopressin | 1 | 1983 | 44 | 0.000 |
Why?
|
| Vasopressins | 1 | 1983 | 61 | 0.000 |
Why?
|
| Anxiety | 1 | 1990 | 1122 | 0.000 |
Why?
|
| Heart | 1 | 1986 | 626 | 0.000 |
Why?
|
| Glucose | 1 | 1986 | 1049 | 0.000 |
Why?
|
| Surveys and Questionnaires | 1 | 1990 | 6085 | 0.000 |
Why?
|